ESTIMATED
05/07/2024
05/07/2024
(AS OF MARCH 31)
Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 1 | $0.69 | $0.69 | $0.69 |
Q2 2024 | 6 | $0.71 | $0.85 | $0.76 |
Q3 2024 | 2 | $1.09 | $1.09 | $1.09 |
Q4 2024 | 2 | $1.27 | $1.27 | $1.27 |
Q1 2025 | 3 | $1.02 | $1.02 | $1.02 |
Q2 2025 | 3 | $1.06 | $1.06 | $1.06 |
Q3 2025 | 3 | $1.18 | $1.18 | $1.18 |
Q4 2025 | 3 | $1.25 | $1.25 | $1.25 |
Halozyme Therapeutics, Inc. last posted its earnings results on Tuesday, May 7th, 2024. The company reported $0.79 earnings per share for the quarter, topping analysts' consensus estimates of $0.7 by $0.09. The company had revenue of 195.88 M for the quarter and had revenue of 829.25 M for the year. Halozyme Therapeutics, Inc. has generated $2 earnings per share over the last year ($2.1 diluted earnings per share) and currently has a price-to-earnings ratio of 20.71. Halozyme Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 6th, 2024 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue | 05/07/2024 | Q1 2024 | $0.70 | $0.61 | -0.09 | $199.74 M | $195.88 M | 02/20/2024 | Q4 2023 | $0.82 | $0.66 | -0.16 | $231.00 M | $230.04 M | 11/06/2023 | Q3 2023 | $0.71 | $0.62 | -0.09 | $216.03 M | 08/08/2023 | Q2 2023 | $0.63 | $0.57 | -0.06 | $221.04 M | 05/09/2023 | Q1 2023 | $0.48 | $0.29 | -0.19 | $179.26 M | $162.14 M | 02/21/2023 | Q4 2022 | $0.47 | $0.43 | -0.04 | $192.05 M | $181.50 M | 11/08/2022 | Q3 2022 | $0.52 | $0.45 | -0.07 | $208.98 M | 08/09/2022 | Q2 2022 | $0.50 | $0.16 | -0.34 | $152.37 M | 05/10/2022 | Q1 2022 | $0.49 | $0.44 | -0.05 | $117.28 M | 02/22/2022 | Q4 2021 | $0.41 | $0.48 | 0.07 | $101.54 M | $102.00 M | 11/02/2021 | Q3 2021 | $0.42 | $1.53 | 1.11 | $105.84 M | $115.83 M | 08/09/2021 | Q2 2021 | $0.41 | $0.64 | 0.23 | $104.12 M | $136.46 M | 05/10/2021 | Q1 2021 | $0.31 | $0.20 | -0.11 | $89.02 M | 02/23/2021 | Q4 2020 | $0.53 | $0.54 | 0.01 | $120.01 M | $121.70 M | 11/02/2020 | Q3 2020 | $0.19 | $0.27 | 0.08 | $59.90 M | $65.32 M | 08/10/2020 | Q2 2020 | $0.25 | $0.19 | -0.06 | $66.68 M | $55.22 M | 05/11/2020 | Q1 2020 | -$0.02 | -$0.04 | -0.02 | $25.35 M | 02/24/2020 | Q4 2019 | -$0.18 | -$0.24 | -0.06 | $56.93 M | $53.67 M | 11/12/2019 | Q3 2019 | -$0.12 | -$0.17 | -0.05 | $54.96 M | $46.23 M | 08/06/2019 | Q2 2019 | -$0.17 | -$0.10 | 0.07 | $42.76 M | $39.15 M |
---|
A. Halozyme Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 6th, 2024 based off last year's report dates.
A. In the previous quarter, Halozyme Therapeutics, Inc. (NASDAQ:HALO) reported $0.79 earnings per share (EPS) to beat the analysts' consensus estimate of $0.7 by $0.09.
A. The conference call for Halozyme Therapeutics, Inc.'s latest earnings report can be listened to online.
A. The conference call transcript for Halozyme Therapeutics, Inc.'s latest earnings report can be read online.
A. Halozyme Therapeutics, Inc. (NASDAQ:HALO) has a recorded annual revenue of $829.25 M.
A. Halozyme Therapeutics, Inc. (NASDAQ:HALO) has a recorded net income of $829.25 M. Halozyme Therapeutics, Inc. has generated $2.13 earnings per share over the last four quarters.
A. Halozyme Therapeutics, Inc. (NASDAQ:HALO) has a price-to-earnings ratio of 20.71 and price/earnings-to-growth ratio is 6.98.